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Relatively little is known for the differentiation and maturation process of human B cells to plasma
cells. This is particularly important in reconstitution work involving transfer of autoantibodies.
To address this issue, we transplanted human peripheral blood mononuclear cells (PBMC) directly into
the spleen of irradiated NOD/SCID mice depleted of natural killer cell activity. Within 6 weeks, naı ¨ve
B cells differentiated into memory B cells and, importantly, the numbers of human CD138
þ plasma
cells in spleen increased by 100 fold after transplantation. Plasma cell numbers correlated with the
detection of human IgM and IgG in serum, indicating that human B cells had differentiated into mature
plasma cells in the murine spleen. In addition to CD19
þ plasma cells, a distinct CD19
2 plasma cell
populationwas detected, suggesting thatdownregulationof CD19 associated withmaturation of plasma
cells occurred. When puriﬁed human B cells were transplanted, those ﬁndings were not observed. Our
results indicate that differentiation and maturation of human B cells and plasma cells can be
investigated by transplantation of human PBMC into the spleen of NOD/SCID mice. The model will be
useful for studying the differentiation of human B cells and generation of plasma cells.
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INTRODUCTION
Plasma cells are terminally differentiated B cells that
produce and secrete antibodies. Little is known about the
development and differentiation of human B cells into
plasma cells due to the low frequency of plasma cells in
the peripheral blood. Murine models, especially immuno-
deﬁcient Prkdcscid=Prkdcscid (SCID) mice engrafted with
human cells (SCID-Hu), have been used to investigate the
development, differentiation and in vivo functions of
human lymphocyte subsets (McCune et al., 1988; Mosier
et al., 1988). Differentiation of human B cells have been
examined by transplanting umbilical cord blood cells into
the scid/scid mice (Mosier et al., 1988; Pﬂumio et al.,
1996; Hogan et al., 1997; Novelli et al., 1999; Rossi et al.,
2001). However, when peripheral blood mononuclear
cells (PBMC) were transplanted intraperitoneally, the
majority of the identiﬁable human cell population were
T cells (Mosier et al., 1988). This has been a particular
problem in attempts to transfer autoimmune disease using
human PBMCs to SCID mice.
Naı ¨ve B cells, following generation in the bone marrow,
migrate to secondary lymphoid organs before they
differentiate into memory B cells and plasma cells
under complex environmental stimuli (Calame, 2001).
The spleen is known to be a major site of B cell
differentiation. To explore the differentiation process of
human B cells, we directly engrafted human PBMC into
spleens of NOD/LtSz-scid/scid (NOD/SCID) mice.
MATERIALS AND METHODS
Engraftment of Human PBMC into NOD/SCID Mice
NOD/SCID mice, aged 4–5 weeks, were obtained from
the Jackson Laboratory (Bar Harbor, ME, USA) and
subsequently maintained by the Animal Resource Service
of the University of California at Davis. Prior to
engraftment, each mouse received 2Gy of total body
irradiation. Each mouse also received an intraperitoneal
injection of an optimal dose of 20ml of rabbit anti-
mouse/rat asialo GM1 polyclonal antibody (Cedarlane
Laboratories, Hornby, Ont., Canada), which recognizes
murine natural killer (NK) cells and depletes NK
activity in vivo (Kasai et al., 1980; Shpitz et al., 1994).
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7 healthy control human PBMC or
4–10£ 10
6 B cells puriﬁed by anti-human CD19
microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) obtained following leukophoresis, in 50mlo f
phosphate-buffered saline (PBS), was directly injected
into the spleen under general anesthesia in groups of
at least 30 mice. After the injection, physiological salt
solution was frequently injected into the peritoneum to
correct for dehydration. Twenty microliters of anti-asialo
GM1 antibody was injected i.p. into each mouse every
5 days. To prevent infection, mice were maintained
in microisolator cages and provided drinking water
supplemented with antibiotics. Three mice were examined
weekly. Single cell suspensions of splenocytes were
prepared by slicing cells from spleen using the end of
slideglass and washed with 0.5% bovine serum albumin
(BSA) in PBS (washing buffer). The cells were counted in
a hemocytometer and viability of cells determined using
trypan blue exclusion.
Flow Cytometric Analysis
PBMC or splenocytes were resuspended in staining buffer
(0.5% BSA, 0.05% sodium azide in PBS) and 25ml
aliquots dispensed into individual tubes. The cells were
ﬁrst pre-incubated with anti-human FcR blocking reagent
(Miltenyi Biotec) and anti-mouse Fc receptor antibody
(eBioscience, San Diego, CA, USA). Cells were stained
with different combinations of the following antibodies
for 15min at 48C: FITC conjugated anti-human CD45,
PE conjugated anti-human CD138, PE-Cy5 conjugated
anti-human CD38, APC conjugated anti-human CD19 or
CD27 (eBioscience), and Cy-Chrome conjugated anti-
human IgM (BD Biosciences, San Diego, CA, USA).
The cells were then washed with washing buffer,
resuspended with 0.05% EDTA in washing buffer and
analyzed with a FACSCalibur (BD Biosciences) ﬂow
cytometer. The acquired data were analyzed with
CELLQUEST software (BD Biosciences).
Determination of Human Ig Levels
Serum samples were collected from three mice every
week and the concentration of human IgG and IgM
determined utilizing an Immuno-Tek human IgM and IgG
EIA Kit (ZeptoMetrix Corporation, Buffalo, NY, USA).
Known positive and negative control samples were
included throughout.
RESULTS
Transfer of Human PBMC into NOD/SCID
Mouse Spleen
To examine the development and differentiation of human
B cells into plasma cells in mouse spleen, we injected
2 £ 10
7 human PBMC or 4 to 10 £ 10
6 B cells directly
into the spleens of NOD/SCID mice that had been
g-irradiated and depleted of NK cell activity. After the
injection, spleens were removed from groups of recipient
mice at weekly intervals and examined by ﬂow cytometric
analysis. As shown in Fig. 1, the number of viable human
mononuclear cells (human CD45
þ cells, Fig. 1A) from
each spleen remained relatively stable for up to 6 weeks
after transplantation (Fig. 1C). By week 7, human cells
were no longer detected in the spleen. Human B cells and
plasma cells, identiﬁed as CD45
þCD19
þCD138
2 and
CD45
þCD138
þ cells respectively (Fig. 1B) (Sanderson
et al., 1989), were also enumerated weekly. The number
of CD19
þ B cells in each spleen remained essentially
unchanged for the ﬁrst 2 weeks after transplantation and
declined gradually thereafter. In contrast, CD138
þ plasma
cells while barely detectable in the PBMC before
transplantation (week 0), increased by more than
100-fold by week 3 and remained readily detectable up
to week 5 (Fig. 1C). The frequency of plasma cells
FIGURE 1 Kinetics of human PBMC subsets grafted into NOD/SCID
mouse spleen. (A) Human cells are deﬁned as CD45
þ. (B) Human B cells
and plasma cells are deﬁned as CD45
þCD19
þCD138
2 and
CD45
þCD138
þ, respectively. (C) The number of total human cells,
human B cells and human plasma cells in each spleen at different time
points following transplantation.
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2.1% of the human cells recovered from mouse spleen at
week 3. These data indicate that human B cells had
differentiated into plasma cells. When puriﬁed human
B cells were transplanted, no cells were detected even
1 week after transplantation (data not shown).
Phenotypic Analysis of Human B Cells
Expression of CD27 has been used as a marker
to distinguish memory B cells from naı ¨ve B cells
(Klein et al., 1998; Tangye et al., 1998). We quantiﬁed
CD19
þ B cells that expressed CD27 before transplanta-
tion (week 0) and at different time points after
transplantation. At week 1 post-transplantation, the
number of CD27
þ memory B cells per spleen increased
while that of CD27
2 naı ¨ve B cells decreased when
compared to those in the transplanted PBMC (week 0)
(Fig. 2A), suggesting that differentiation of naı ¨ve B
cells into memory B cells occurred during the ﬁrst
week after transplantation. The frequency of CD27
þ
memory B cells in the total CD19
þ B cell population
increased steadily while the number of both memory
and naı ¨ve B cells declined after week 1 (Fig. 2B),
suggesting that memory B cells have a longer life span
than naı ¨ve B cells in the mouse spleen. Alternatively,
this may indicate that some naı ¨ve B cells continued
to differentiate into memory B cells during this
time period.
We also examined the expression of sIgM by B cells.
At all time points examined, both IgM
þ and IgM
2
memory and naı ¨ve B cells were detected. The overall
frequency of IgM
þ B cells declined from 68% at week 0
to 27% at week 5 after transplantation (Fig. 2C). Of note,
most of this change is attributed to the decrease of naı ¨ve
B cells (CD27
2) that expressed IgM. In PBMC before
transplantation, 50% of B cells are CD27
2IgM
þ; while
5 weeks after transplantation, 69% of B cells are
CD27
þIgM
2 (Fig. 2D), again suggesting that IgM
2
memory B cells have a longer life span.
Phenotypic Analysis of Human Plasma Cells
We analyzed the expression of the cell surface markers
CD19, CD38 and IgM on CD138
þ plasma cells recovered
from mouse spleen. As shown in Fig. 3A, plasma cells
were found in both CD19
þ and CD19
2 compartments at
all time points examined (Fig. 3A). The majority of
plasma cells expressed CD38, however, 13% of plasma
cells in the CD19 negative population were CD38
2 at
week 5 (Fig. 3B). Changes in the frequency of IgM
þ
plasma cells were within the CD19
þ and CD19
2
populations. Between week 3 to week 5, it declined
from 39 to 10% in CD19
þ population, but remained
unchanged in the CD19
2 population (Fig. 3C).
Detection of Human Immunoglobulin in Mouse Serum
As shown in Fig. 4, the concentration of both human IgG
and IgM in mouse serum increased signiﬁcantly after
transplantation. The peak concentration correlated with
the peak of plasma cells, indicating that the human plasma
cells generated in the mouse spleen are functional.
The concentration of IgM started to decline at week 5
and became undetectable at week 7, while that of IgG
remained little changed until week 6. By week 7
a signiﬁcant level of IgG can still be detected, suggesting
that the IgG-producing plasma cells have a longer
life-span than IgM-producing cells.
FIGURE 2 Kinetics and phenotype of engrafted human B cells. Human
naı ¨ve and memory B cells are deﬁned as CD45
þCD19
þCD27
2 and
CD45
þCD19
þCD27
þ, respectively. (A) The number of human naı ¨ve and
memory B cells in each spleen at different time points following
transplantation. (B) Kinetics of memory B cell frequency; the number
in the histogram is the percentage of CD27
þ cells in the CD45
þCD19
þ
B cell population. (C) Kinetics of surface IgM
þ B cell frequency;
the number in the histogram is the percentage of surface IgM
þ cells in the
CD45
þCD19
þ B cell population. The unﬁlled graph indicates
the histogram of cells with isotype control antibody. (D) Transition of
surface IgM
þ cell frequency in naı ¨ve and memory B cells. Cells are gated
on the CD45
þCD19
þ B cell populations. The numbersin the dot plots are
percentage of cells in each quadrant.
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We studied herein the differentiation of human B cells
using a SCID-Hu mouse model. Human PBMC were
transplanted into spleens of NOD/SCID mice following
irradiation and depletion of NK cell activity. Human cells
were found to survive in the mouse spleen for up to
6 weeks. The number of plasma cells greatly increased,
with high circulating levels of both human IgG and IgM.
Our results indicate that human B cells can differentiate
into mature plasma cells in the murine spleen. To our
knowledge this is the ﬁrst observation of newly
differentiated plasma cells in SCID-Hu mice using the
direct intrasplenic injection method.
SpleenisknowntobeamajorsiteforBcelldifferentiation
andplasmacellmaturation,aprocessthathasnotbeenfully
characterized.ArecentstudyfoundthatwhenhumanPBMC
were engrafted into the spleen of irradiated NOD/SCID
mice, B cells became activated and differentiated into
plasmacytoid cells (Depraetere et al., 2001). However, the
engrafted B cells were followed for a relatively short time
period,becausealmostallmicediedofgraft-vs-hostdisease
(GVHD) within 3–4 weeks after transplantation. For this
reason, terminally differentiated plasma cells have not been
characterized in detail (Depraetere et al., 2001). Successful
transplantation of human cells into mice requires both
irradiationanddepletionofNKcellactivityinrecipientmice
(Shultzetal.,1995).Irradiationofthemicemayaugmentthe
capacity of murine spleen for the differentiation of
transplanted human cells. However, high dose irradiation
may also cause severe GVHD, resulting in early death of
mice that limits the time span for following transplanted
human cells. In this study, we irradiated the mice with a
lower dose than that previously reported (2Gy vs. 3Gy)
(Depraetere et al., 2001). Our procedure resulted in a
signiﬁcantly improved animal survival of 9 weeks after
transplantation (data not shown), without compromising
the capability of irradiated mouse spleen to support
the differentiation of engrafted B cells.
AntigenstimulationfollowedbyTcellhelpinitiatesnaı ¨ve
BcellsdifferentiationintomemoryBcellsandplasmacells.
For B cell differentiation to occur, activated T cell help
including CD40/CD40L interactions are required. This
requirement has also been shown in SCID-Hu mice.
In addition, interaction of tumor-necrosis factor (TNF)
family ligands and their receptors play an important role in
the splenic environment for B cell differentiation (Fu and
Chaplin, 1999). Recently, a member of TNF family, BLyS
(B lymphocyte stimulation, also named BAFF or TALL-1)
has been found to express on T cells, dendritic cells,
monocytes and macrophages. We postulate that injection of
humanPBMCintothespleenofNOD/SCIDmouseleadsto
dysregulation of BLyS and/or its receptor, resulting in the
differentiation of B cells and generation of plasma cells.
Since transplantation of puriﬁed human B cells into the
mouse spleen did not lead to similar results, we believe that
other non-B cell factors are necessary in the differentiation
and maturation of B cells.
Naı ¨ve B cells are generated in the bone marrow. From
there they migrate into spleen, some stay at the marginal
zone while others localize to the follicle. In the marginal
zone, naı ¨ve B cells are activated by antigen. The activated
B cells form foci in the extrafollicular region and
differentiate into plasma cells that produce low-afﬁnity
IgM as a primary antibody response (Calame, 2001).
The IgM-producing plasma cells die by apoptosis after a
short life span (Smith et al.,1 9 9 6 ;D a lP o r t oet al.,1 9 9 8 ) .
On the other hand, if the follicle occurs within the germinal
center,theybecomememoryBcellsandswitchisotypeinto
high afﬁnity IgG-producing plasma cells facilitated by
CD40/CD40L interactions (Arpin et al., 1995). These cells
home to the bone marrow and their life span is long
FIGURE 3 Phenotype of human plasma cells recovered from mouse
spleen.HumanplasmacellsaredeﬁnedasCD45
þCD138
þ.(A)Frequency
of CD19
þ and CD19
2 plasma cells; the numbers in the dot plots are the
percentage of CD19
þ and CD19
2 plasma cells in the recovered CD45
þ
humancells.(B)ExpressionofCD38andCD19byCD138
þplasmacells.
CellsaregatedonCD45
þCD138
þplasmacellpopulation;thenumbersin
the dot plots are percentage of cells in each quadrant. (C) Expression of
cell surface IgM and CD19 on CD138
þ plasma cells; the numbers in the
dot plots are the percentage of cells in each quadrant.
FIGURE 4 Serum concentration of human immunoglobulins in mice
receiving human PBMC.
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expression of CD38 inhibits apoptosis (Zupo et al.,1 9 9 4 ) ,
suggesting that the CD38
þ population is long-lived. It has
been reported that plasma cells which differentiate in the
spleen germinal center were CD19
þCD138
þ (Angelin-
Duclos et al., 2000), a phenotype called early plasma cells
(Jego et al.,1 9 9 9 ) .
Our ﬁnding is in agreement with the thesis that naı ¨ve
B cells are activated and differentiate into memory B cells
within the spleen. During the ﬁrst week after engraftment,
the number of CD27
2 naı ¨ve B cells declined while that of
CD27
þ memory B cells increased (Fig. 2A). The greatly
increased number of plasma cells after transplantation as
wellastheconcurrentdetectionofhighlevelsofhumanIgG
and IgM in the mouse serum indicates that human B cells
have differentiated into functional plasma cells.
At week 3 after transplantation, most plasma cells express
IgM (Fig. 3C), suggesting these are the short-life
IgM-producing plasma cells which differentiate in the
extrafollicular region (Smith et al., 1996; Dal Porto et al.,
1998). By week 5, most of the plasma cells were
CD38
þIgM
2, suggesting that they are IgG-producing
long-lifeplasmacells(Arpinetal.,1995;Slifkaetal.,1998).
In this work we used CD138 as the marker to deﬁne
plasma cells because it has been reported to be a more
speciﬁc marker for plasma cells than CD38, as the latter is
also expressed by activated B cells or plasmablasts
(Sanderson et al., 1989; Wijdenes et al., 1996; Jego et al.,
1999; Deaglio et al., 2001). With the use of this marker,
we found that in addition to CD19
þCD138
þ plasma
cells as previously described (Jego et al., 1999),
CD19
2CD138
þ plasma cells were also detected
(Fig. 3A). It is known that when CD19
þ plasma cells
migrate from the peripheral blood to bone marrow, CD19
expression is down-regulated during the process of
maturation (Medina et al., 2002). Our observation
suggests that the downregulation of CD19 expression
may also occur in the spleen. However, the origin and
function of the CD19
2 plasma cells we identiﬁed need to
be further characterized.
Thus we have established a SCID-Hu mouse model that
appears to be physiologically capable to allow the
differentiation process of human B cells into mature and
functional plasma cells. A traceable population of
CD138
þ plasma cells can be followed for up to 6 weeks
after transplantation of human PBMC into the mouse
spleen. Differentiation of B cells and generation of plasma
cells plays important roles in the regulation of normal and
abnormal B cell immunity. This system will be useful for
studying the generation of protective antibodies against
infection, as well as the generation of antibodies involved
in autoimmune diseases.
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